Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis
- PMID: 30143889
- DOI: 10.1007/s00787-018-1217-x
Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis
Abstract
This meta-analysis was conducted to evaluate the association between Attention deficit hyperactivity disorder (ADHD) medications and risk of sudden death/arrhythmia, stroke, myocardial infarction as well as all-cause death. We searched PubMed, Web of Science and China National Knowledge Infrastructure from 1950 to May 2018. All observational studies that the exposure of interest was ADHD medications, the outcome of interest was sudden death/arrhythmia, stroke, myocardial infarction as well as all-cause death, and the study reported relative risks (RRs) with 95% confidence intervals (95% CIs) were included. Pooled RRs were estimated by random-effects model. Subgroup analyses were conducted to examine the effects of study design, population, Country, follow-up duration, female proportion, covariates adjustment on the risk of sudden death/arrhythmia. Eight articles with ten studies (4,221,929 participants) were included in this meta-analysis about the association between ADHD medications and risk of sudden death/arrhythmia. The pooled RRs with 95% CIs of sudden death/arrhythmia for ADHD medications were 1.39 (1.06, 1.83). The result of the cohort study was 1.24 (0.84, 1.83). The pooled RRs between ADHD medications and stroke, myocardial infarction, all-cause death were 1.00 (0.74, 1.35), 0.91 (0.79, 1.05), 0.89 (0.54, 1.45), respectively. As for methylphenidate, the pooled RRs between methylphenidate and sudden death/arrhythmia, stroke, myocardial infarction, all-cause death were 1.46 (1.03, 2.07), 0.92 (0.70, 1.21), 0.97 (0.77, 1.23), 1.00 (0.49, 2.04), respectively. Based on the results of cohort studies, there was no correlation between ADHD medications and sudden death/arrhythmia, stroke, myocardial infarction and all-cause death. However, some of the confidence intervals do not exclude modest elevated risks, e.g., for sudden death/arrhythmia.
Keywords: ADHD medications; All-cause death; Meta-analysis; Myocardial infarction; Stroke; Sudden death/arrhythmia.
Similar articles
-
Cardiovascular events and death in children exposed and unexposed to ADHD agents.Pediatrics. 2011 Jun;127(6):1102-10. doi: 10.1542/peds.2010-3371. Epub 2011 May 16. Pediatrics. 2011. PMID: 21576311 Free PMC article.
-
Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis.JAMA Netw Open. 2022 Nov 1;5(11):e2243597. doi: 10.1001/jamanetworkopen.2022.43597. JAMA Netw Open. 2022. PMID: 36416824 Free PMC article.
-
[Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].Arch Pediatr. 2014 Jan;21(1):108-12. doi: 10.1016/j.arcped.2013.11.001. Epub 2013 Dec 3. Arch Pediatr. 2014. PMID: 24309201 French.
-
Oral contraceptive use and cardiovascular disease: is the relationship real or due to study bias?J Fam Pract. 1992 Aug;35(2):147-57. J Fam Pract. 1992. PMID: 1386621
-
Meta-analysis of adverse cardiovascular outcomes associated with antecedent hypertension after myocardial infarction.Am J Cardiol. 2009 Jul 1;104(1):141-7. doi: 10.1016/j.amjcard.2009.02.048. Epub 2009 May 4. Am J Cardiol. 2009. PMID: 19576336 Review.
Cited by
-
Identification and treatment of individuals with attention-deficit/hyperactivity disorder and substance use disorder: An expert consensus statement.World J Psychiatry. 2023 Mar 19;13(3):84-112. doi: 10.5498/wjp.v13.i3.84. eCollection 2023 Mar 19. World J Psychiatry. 2023. PMID: 37033892 Free PMC article. Review.
-
From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care.J Child Adolesc Psychopharmacol. 2024 May;34(4):167-182. doi: 10.1089/cap.2024.0022. Epub 2024 Apr 30. J Child Adolesc Psychopharmacol. 2024. PMID: 38686563 Free PMC article. Review.
-
Causal relationship between attention deficit hyperactivity disorder and atherosclerosis: A bidirectional Mendelian randomization study.Medicine (Baltimore). 2025 Jun 27;104(26):e42859. doi: 10.1097/MD.0000000000042859. Medicine (Baltimore). 2025. PMID: 40587750 Free PMC article.
-
Effectiveness and safety of dexamphetamine sulfate (Attentin®) in the routine treatment of children and adolescents with ADHD: results from a 12-month non-interventional study.Scand J Child Adolesc Psychiatr Psychol. 2021 Apr 23;9:73-86. doi: 10.21307/sjcapp-2021-009. eCollection 2021. Scand J Child Adolesc Psychiatr Psychol. 2021. PMID: 33928056 Free PMC article.
-
Comparative cardiovascular side effects of medications for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.BMJ Open. 2022 Sep 26;12(9):e062748. doi: 10.1136/bmjopen-2022-062748. BMJ Open. 2022. PMID: 36167386 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials